Last reviewed · How we verify

Active bupropion-Placebo gum

University of Wisconsin, Madison · FDA-approved active Small molecule

Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to reduce cravings and withdrawal symptoms during smoking cessation.

Bupropion is a norepinephrine-dopamine reuptake inhibitor that increases levels of these neurotransmitters in the brain to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid.

At a glance

Generic nameActive bupropion-Placebo gum
SponsorUniversity of Wisconsin, Madison
Drug classNorepinephrine-dopamine reuptake inhibitor (NDRI)
TargetNorepinephrine transporter (NET) and dopamine transporter (DAT)
ModalitySmall molecule
Therapeutic areaPsychiatry / Smoking Cessation
PhaseFDA-approved

Mechanism of action

Bupropion blocks the reuptake of norepinephrine and dopamine at the neuronal synapse, increasing their availability in the central nervous system. This mechanism helps counteract the dopamine deficit that occurs when nicotine is withdrawn, reducing both cravings and negative mood symptoms associated with smoking cessation. The gum formulation allows for local delivery and sustained release in the oral cavity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: